This Practice Point commentary discusses a recent paper by Hoving et al., who compared the cost-effectiveness of continuous intrathecal baclofen infusion (CIBI) with that of 'standard care' in ...

Study design: Retrospective single centre study. Objectives: To evaluate a low-dose radioisotope imaging procedure for assessment of implanted intrathecal drug delivery and to compare the radiation ...

PRIALT ® (ziconotide) is the only FDA-approved, non-opioid intrathecal infusion treatment option for patients suffering from severe chronic pain for whom intrathecal therapy is warranted, and who are ...

image: Transduced cells cluster around blood vessels in the rat brain after intrathecal AAV9 infusion. AAV9 in the cerebrospinal fluid is thought to enter the brain by flow along the Virchow Robin ...

image: Transduced neurons in rat cortex express the reporter gene eGFP after intrathecal AAV9 infusion. This material relates to a paper that appeared in the Nov. 14th, 2018, issue of Science Advances ...

Researchers have generated more preclinical evidence that intranasal delivery can get antibodies to the brain, presenting data that suggest the administration route can achieve concentrations close to ...

PRIALT is a non-opioid intrathecal analgesic indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other ...

TerSera Therapeutics LLC today announced that it has completed the previously announced sale of its Infusion Specialty Therapies Business Unit (IST), including two specialty medications, Prialt ® ...